Recurrent Lung Non-Small Cell CarcinomaPhase 3NCT05633602
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
A Phase 3 study testing Chemotherapy, Pembrolizumab and Ramucirumab in people with Recurrent Lung Non-Small Cell Carcinoma and Stage IV Lung Cancer AJCC v8, run by SWOG Cancer Research Network at 566 sites in United States.
Trial summary
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- What is being tested?
- Chemotherapy, Pembrolizumab and Ramucirumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 838 participants
- Where
- 566 sitesUnited States
- Study dates
- 14 Mar 2023to 15 Mar 2028
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) which is stage IV or recurrent
- Participants must have received at least one line of anti-PD-1 or anti-PD-L1 therapy for any stage of NSCLC. Anti-PD-1 or anti-PD-L1 may have been given alone or in combination with other therapy
- Participants must have experienced disease progression (in the opinion of the treating physician) more than (>) 84 days following initiation (cycle 1 day 1) of their most recent anti-PD-1 or PD-L1 therapy
- Participants who received anti-PD-1 or anti-PD-L1 therapy for stage IV or recurrent disease, must have had a best response on anti-PD-1 or anti-PD-L1 therapy of stable, partial response or complete response (in the opinion of the treating physician)
- Participants who received neoadjuvant, adjuvant, and/or consolidation anti-PD-1 or anti-PD-L1 therapy as their only line of anti-PD-1 or anti-PD-L1 therapy must have experienced disease progression within (=<) 365 days from initiation (cycle 1 day 1) of anti-PD-1 or PD-L1 therapy
- Participants must have received platinum-based chemotherapy and experienced disease progression (in the opinion of the treating physician) during or after this regimen
Show all 10Show fewer
- Participants with a known sensitizing mutation for which an Food and Drug Administration (FDA)-approved targeted therapy for NSCLC exists (e.g., EGFR, ALK, ROS1, BRAF, RET, NTRK, KRAS, HER2 and MET sensitizing mutations), must have previously received at least one of the approved therapy(s). Prior targeted therapy for participants with targetable alterations is allowed if all other eligibility criteria are also met
- Participants must be >= 18 years old
- Participants must be able to safely receive the investigational drug combination and the investigator's choice of standard of care regimens per the current FDA approved package insert(s), treating investigator's discretion, and institutional guidelines
- Participants must have Zubrod performance status of 0-2
Who cannot join
- Participants must not have received more than one line of anti-PD-1 or anti-PD-L1 for stage IV or recurrent disease
- Participants must not be receiving or planning to receive another investigational therapy during study participation
Trial locations and contacts
566 sites in 1 country.
300 sites in 1 country
United States300 sites
Hawaii Cancer Care - Westridge
‘Aiea, Hawaii, 96701
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
Summa Health System - Akron Campus
Akron, Ohio, 44304
Cleveland Clinic Akron General
Akron, Ohio, 44307
Atrium Health Stanly/LCI-Albemarle
Albemarle, North Carolina, 28002
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87102
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
UPMC Altoona
Altoona, Pennsylvania, 16601
The Don and Sybil Harrington Cancer Center
Amarillo, Texas, 79106
Community Hospital of Anaconda
Anaconda, Montana, 59711
Kaiser Permanente-Anaheim
Anaheim, California, 92806
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
Langlade Hospital and Cancer Center
Antigo, Wisconsin, 54409
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
PCR Oncology
Arroyo Grande, California, 93420
AdventHealth Infusion Center Asheville
Asheville, North Carolina, 28803
King's Daughter's Medical Center
Ashland, Kentucky, 41101
Northside Hospital
Atlanta, Georgia, 30342
Sutter Auburn Faith Hospital
Auburn, California, 95602
Rocky Mountain Regional VA Medical Center
Aurora, Colorado, 80045
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045
Rush - Copley Medical Center
Aurora, Illinois, 60504
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida, 33180
Kaiser Permanente-Baldwin Park
Baldwin Park, California, 91706
Greater Baltimore Medical Center
Baltimore, Maryland, 21204
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
Kaiser Permanente-Woodlawn Medical Center
Baltimore, Maryland, 21244
Summa Health System - Barberton Campus
Barberton, Ohio, 44203
Advocate Good Shepherd Hospital
Barrington, Illinois, 60010
Louisiana Hematology Oncology Associates LLC
Baton Rouge, Louisiana, 70809
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
Bronson Battle Creek
Battle Creek, Michigan, 49017
Houston Methodist San Jacinto Hospital
Baytown, Texas, 77521
UPMC-Heritage Valley Health System Beaver
Beaver, Pennsylvania, 15009
Kaiser Permanente-Bellflower
Bellflower, California, 90706
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, 98225
Strecker Cancer Center-Belpre
Belpre, Ohio, 45714
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, 56601
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Walter Reed National Military Medical Center
Bethesda, Maryland, 20889-5600
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
University of Iowa Healthcare Cancer Services Quad Cities
Bettendorf, Iowa, 52722
Beverly Hospital
Beverly, Massachusetts, 01915
Tower Cancer Research Foundation
Beverly Hills, California, 90211
Billings Clinic Cancer Center
Billings, Montana, 59101
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Saint Joseph's/Candler - Bluffton Campus
Bluffton, South Carolina, 29910
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Saint Luke's Cancer Institute - Boise
Boise, Idaho, 83712
Boston Medical Center
Boston, Massachusetts, 02118
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Saint Joseph Mercy Brighton
Brighton, Michigan, 48114
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan, 48114
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin, 53105
UPMC Hillman Cancer Center at Butler Health System
Butler, Pennsylvania, 16001
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, 83605
Cooper Hospital University Medical Center
Camden, New Jersey, 08103
Marshall Cancer Center
Cameron Park, California, 95682
UPMC Camp Hill
Camp Hill, Pennsylvania, 17011
Illinois CancerCare-Canton
Canton, Illinois, 61520
Saint Joseph Mercy Canton
Canton, Michigan, 48188
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, Michigan, 48188
Cleveland Clinic Mercy Hospital
Canton, Ohio, 44708
Aultman Health Foundation
Canton, Ohio, 44710
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Carlisle Regional Cancer Center
Carlisle, Pennsylvania, 17015
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Rex Hematology Oncology Associates-Cary
Cary, North Carolina, 27518
Mercy Hospital
Cedar Rapids, Iowa, 52403
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Miami Valley Hospital South
Centerville, Ohio, 45459
WellSpan Medical Oncology and Hematology
Chambersburg, Pennsylvania, 17201
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599
Medical University of South Carolina
Charleston, South Carolina, 29425
West Virginia University Charleston Division
Charleston, West Virginia, 25304
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, 28203
Atrium Health Pineville/LCI-Pineville
Charlotte, North Carolina, 28210
Levine Cancer Institute-SouthPark
Charlotte, North Carolina, 28211
Atrium Health University City/LCI-University
Charlotte, North Carolina, 28262
Levine Cancer Institute-Ballantyne
Charlotte, North Carolina, 28277
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
Saint Joseph Mercy Chelsea
Chelsea, Michigan, 48118
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan, 48118
Northwestern University
Chicago, Illinois, 60611
University of Illinois
Chicago, Illinois, 60612
Swedish Covenant Hospital
Chicago, Illinois, 60625
Advocate Illinois Masonic Medical Center
Chicago, Illinois, 60657
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, 63376
Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio, 44111
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina, 28328
AdventHealth Infusion Center Haywood
Clyde, North Carolina, 28721
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho, 83814
Baptist Memorial Hospital and Cancer Center-Collierville
Collierville, Tennessee, 38017
UCHealth Memorial Hospital Central
Colorado Springs, Colorado, 80909
Memorial Hospital North
Colorado Springs, Colorado, 80920
Baptist Memorial Hospital and Cancer Center-Golden Triangle
Columbus, Mississippi, 39705
Mount Carmel East Hospital
Columbus, Ohio, 43213
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Atrium Health Cabarrus/LCI-Concord
Concord, North Carolina, 28025
Mercy Hospital
Coon Rapids, Minnesota, 55433
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, 33146
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141
Northwest Cancer Center - Main Campus
Crown Point, Indiana, 46307
AMG Crystal Lake - Oncology
Crystal Lake, Illinois, 60014
UPMC Western Maryland
Cumberland, Maryland, 21502
Dallas VA Medical Center
Dallas, Texas, 75216
Carle at The Riverfront
Danville, Illinois, 61832
Geisinger Medical Center
Danville, Pennsylvania, 17822
Dayton Blood and Cancer Center
Dayton, Ohio, 45409
Miami Valley Hospital
Dayton, Ohio, 45409
Dayton Physician LLC-Miami Valley Hospital North
Dayton, Ohio, 45415
Miami Valley Hospital North
Dayton, Ohio, 45415
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, 33442
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois, 60115
Kaiser Permanente-Franklin
Denver, Colorado, 80205
Smilow Cancer Hospital-Derby Care Center
Derby, Connecticut, 06418
Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa, 50309
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Ascension Saint John Hospital
Detroit, Michigan, 48236
Illinois CancerCare-Dixon
Dixon, Illinois, 61021
Advocate Good Samaritan Hospital
Downers Grove, Illinois, 60515
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Kaiser Permanente Dublin
Dublin, California, 94568
Northside Hospital - Duluth
Duluth, Georgia, 30096
Duke University Medical Center
Durham, North Carolina, 27710
Northwest Oncology LLC
Dyer, Indiana, 46311
Great Lakes Cancer Management Specialists-Doctors Park
East China, Michigan, 48054
Pocono Medical Center
East Stroudsburg, Pennsylvania, 18301
HSHS Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Fairview Southdale Hospital
Edina, Minnesota, 55435
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Crossroads Cancer Center
Effingham, Illinois, 62401
Advocate Sherman Hospital
Elgin, Illinois, 60123
Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus
Elizabeth, New Jersey, 07207
Arnot Ogden Medical Center/Falck Cancer Center
Elmira, New York, 14905
Ephrata Cancer Center
Ephrata, Pennsylvania, 17522
UPMC Hillman Cancer Center Erie
Erie, Pennsylvania, 16505
Green Bay Oncology - Escanaba
Escanaba, Michigan, 49829
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, 60201
Smilow Cancer Hospital Care Center-Fairfield
Fairfield, Connecticut, 06824
Sanford Broadway Medical Center
Fargo, North Dakota, 58122
Sanford Roger Maris Cancer Center
Fargo, North Dakota, 58122
Parkland Health Center - Farmington
Farmington, Missouri, 63640
UPMC Cancer Center at UPMC Horizon
Farrell, Pennsylvania, 16121
Highlands Oncology Group - Fayetteville
Fayetteville, Arkansas, 72703
Genesee Cancer and Blood Disease Treatment Center
Flint, Michigan, 48503
Genesee Hematology Oncology PC
Flint, Michigan, 48503
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
McLeod Regional Medical Center
Florence, South Carolina, 29506
Kaiser Permanente-Fontana
Fontana, California, 92335
Levine Cancer Institute - Rutherford
Forest City, North Carolina, 28043
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado, 80528
Eisenhower Army Medical Center
Fort Gordon, Georgia, 30905-5650
Mercy Hospital Fort Smith
Fort Smith, Arkansas, 72903
Tarrant County Hospital District/JPS Health Network
Fort Worth, Texas, 76104
Beebe South Coastal Health Campus
Frankford, Delaware, 19945
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Kaiser Permanente-Fremont
Fremont, California, 94538
Palo Alto Medical Foundation-Fremont
Fremont, California, 94538
Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho, 83619
Malcom Randall Veterans Administration Medical Center
Gainesville, Florida, 32610
Northeast Georgia Medical Center-Gainesville
Gainesville, Georgia, 30501
Kaiser Permanente-Gaithersburg Medical Center
Gaithersburg, Maryland, 20879
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Rex Hematology Oncology Associates-Garner
Garner, North Carolina, 27529
Levine Cancer Institute-Gaston
Gastonia, North Carolina, 28054
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, 60134
Tidelands Georgetown Memorial Hospital
Georgetown, South Carolina, 29440
Aurora Health Care Germantown Health Center
Germantown, Wisconsin, 53022
Adams Cancer Center
Gettysburg, Pennsylvania, 17325
Smilow Cancer Hospital Care Center at Glastonbury
Glastonbury, Connecticut, 06033
NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois, 60026
Addison Gilbert Hospital
Gloucester, Massachusetts, 01930
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina, 27534
Aurora Cancer Care-Grafton
Grafton, Wisconsin, 53024
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
UCHealth Greeley Hospital
Greeley, Colorado, 80631
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
UPMC Cancer Centers - Arnold Palmer Pavilion
Greensburg, Pennsylvania, 15601
Miami Valley Cancer Care and Infusion
Greenville, Ohio, 45331
Smilow Cancer Hospital Care Center at Greenwich
Greenwich, Connecticut, 06830
Gibbs Cancer Center-Pelham
Greer, South Carolina, 29651
Baptist Cancer Center-Grenada
Grenada, Mississippi, 38901
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Grosse Pointe Woods, Michigan, 48236
Michigan Breast Specialists-Grosse Pointe Woods
Grosse Pointe Woods, Michigan, 48236
Smilow Cancer Hospital Care Center - Guilford
Guilford, Connecticut, 06437
Gulfport Memorial Hospital
Gulfport, Mississippi, 39502
The Cancer Institute of New Jersey Hamilton
Hamilton, New Jersey, 08690
Kaiser Permanente - Harbor City
Harbor City, California, 90710
UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Harrisburg, Pennsylvania, 17109
Hartford Hospital
Hartford, Connecticut, 06102
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, 06105
HaysMed University of Kansas Health System
Hays, Kansas, 67601
Advocate South Suburban Hospital
Hazel Crest, Illinois, 60429
AdventHealth Hendersonville
Hendersonville, North Carolina, 28792
NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois, 60035
South Carolina Cancer Specialists PC
Hilton Head Island, South Carolina, 29926-3827
Edward Hines Jr VA Hospital
Hines, Illinois, 60141
Northwest Cancer Center - Hobart
Hobart, Indiana, 46342
Saint Mary Medical Center
Hobart, Indiana, 46342
Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu, Hawaii, 96813
Queen's Cancer Cenrer - POB I
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital
Honolulu, Hawaii, 96813
Queen's Cancer Center - Kuakini
Honolulu, Hawaii, 96817
Kaiser Permanente Moanalua Medical Center
Honolulu, Hawaii, 96819
Terrebonne General Medical Center
Houma, Louisiana, 70360
Lyndon Baines Johnson General Hospital
Houston, Texas, 77026-1967
Houston Methodist Hospital
Houston, Texas, 77030
Methodist Willowbrook Hospital
Houston, Texas, 77070
Edwards Comprehensive Cancer Center
Huntington, West Virginia, 25701
City of Hope at Huntington Beach
Huntington Beach, California, 92648
Cleveland Clinic Cancer Center Independence
Independence, Ohio, 44131
IRMC Cancer Center
Indiana, Pennsylvania, 15701
Saint Catherine Hospital
Indianapolis, Indiana, 46312
City of Hope at Irvine Lennar
Irvine, California, 92618
Kaiser Permanente-Irvine
Irvine, California, 92618
Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina, 28546
Jersey City Medical Center
Jersey City, New Jersey, 07302
UPMC-Johnstown/John P. Murtha Regional Cancer Center
Johnstown, Pennsylvania, 15901
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Ascension Borgess Cancer Center
Kalamazoo, Michigan, 49009
Borgess Medical Center
Kalamazoo, Michigan, 49048
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Truman Medical Centers
Kansas City, Missouri, 64108
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
Kansas City Veterans Affairs Medical Center
Kansas City, Missouri, 64128
Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin, 53142
Kettering Medical Center
Kettering, Ohio, 45429
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Kaiser Permanente-Rock Creek
Lafayette, Colorado, 80026
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois, 60045
The Watson Clinic
Lakeland, Florida, 33805
Monmouth Medical Center Southern Campus
Lakewood, New Jersey, 08701
City of Hope Antelope Valley
Lancaster, California, 93534
Fairfield Medical Center
Lancaster, Ohio, 43130
Lancaster General Ann B Barshinger Cancer Institute
Lancaster, Pennsylvania, 17601
Sparrow Hospital
Lansing, Michigan, 48912
Kaiser Permanente - Largo Medical Center
Largo, Maryland, 20774
OptumCare Cancer Care at Charleston
Las Vegas, Nevada, 89102
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada, 89148
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Northside Hospital - Gwinnett
Lawrenceville, Georgia, 30046
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire, 03756
Sechler Family Cancer Center
Lebanon, Pennsylvania, 17042
Saint Luke's East - Lee's Summit
Lee's Summit, Missouri, 64086
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536
AMG Libertyville - Oncology
Libertyville, Illinois, 60048
Condell Memorial Hospital
Libertyville, Illinois, 60048
Atrium Health Lincoln/LCI-Lincolnton
Lincolnton, North Carolina, 28092
John L McClellan Memorial Veterans Hospital
Little Rock, Arkansas, 72205
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Saint Barnabas Medical Center
Livingston, New Jersey, 07039
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan, 48154
Loma Linda University Medical Center
Loma Linda, California, 92354
Kaiser Permanente-Lone Tree
Lone Tree, Colorado, 80124
UCHealth Lone Tree Health Center
Lone Tree, Colorado, 80124
City of Hope at Long Beach Elm
Long Beach, California, 90813
Monmouth Medical Center
Long Branch, New Jersey, 07740
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027
Kaiser Permanente West Los Angeles
Los Angeles, California, 90034
Cedars Sinai Medical Center
Los Angeles, California, 90048
Medical Center of the Rockies
Loveland, Colorado, 80538
Kaiser Permanente Lutherville - Timonium Medical Center
Lutherville, Maryland, 21093
Centra Lynchburg Hematology-Oncology Clinic Inc
Lynchburg, Virginia, 24501
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Great Lakes Cancer Management Specialists-Macomb Medical Campus
Macomb, Michigan, 48044
Michigan Breast Specialists-Macomb Township
Macomb, Michigan, 48044
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792
Cleveland Clinic Cancer Center Mansfield
Mansfield, Ohio, 44906
Fairview Clinics and Surgery Center Maple Grove
Maple Grove, Minnesota, 55369
Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin, 54143
Fremont - Rideout Cancer Center
Marysville, California, 95901
Memorial Hospital
Marysville, Ohio, 43040
Levine Cancer Institute - Union West
Matthews, North Carolina, 28104
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Hillcrest Hospital Cancer Center
Mayfield Heights, Ohio, 44124
Loyola University Medical Center
Maywood, Illinois, 60153
UPMC Cancer Center at UPMC McKeesport
McKeesport, Pennsylvania, 15132
Kaiser Permanente Tysons Corner Medical Center
McLean, Virginia, 22102
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Mechanicsburg, Pennsylvania, 17050
About this study
Official title: Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Read the detailed description
PRIMARY OBJECTIVE:
- To compare overall survival (OS) in participants previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC) randomized to pembrolizumab and ramucirumab versus standard of care.
SECONDARY OBJECTIVE:
- To summarize reports of serious and unexpected high-grade (>= grade 3) treatment-related adverse events determined by the treating physician within each treatment arm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive chemotherapy per standard of care on study.
ARM B: Patients receive ramucirumab intravenously (IV) and pembrolizumab IV on study.
- Being tested
- Chemotherapy, Pembrolizumab, Ramucirumab
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ChemotherapyDrug
Also called Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General
Receive standard of care chemotherapy
PembrolizumabBiological
Also called Keytruda, Lambrolizumab, MK-3475, SCH 900475
Given IV
RamucirumabBiological
Also called Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
Given IV
| Study group | Role | What they receive |
|---|---|---|
| ARM A (standard of care chemotherapy) | Active comparator | Patients receive chemotherapy per standard of care on study. Receives: Drug: Chemotherapy |
| ARM B (ramucirumab, pembrolizumab) | Experimental | Patients receive ramucirumab IV and pembrolizumab IV on study. Receives: Biological: Pembrolizumab; Biological: Ramucirumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Assessed in participants with stage IV or recurrent non-small cell lung cancer with acquired resistance to anti-PD-1 or anti-PD-L1 therapy randomized to ramucirumab and pembrolizumab or standard of care chemotherapy. Will use an intention-to-treat analysis and the comparison will be done using a stratified log-rank test. The distribution of overall survival will be estimated using the method of Kaplan-Meier and a Cox proportional hazards model will be used to estimate hazard ratios and associated 95% confidence intervals to estimate treatment effects.
Measured: From date of randomization to date of death due to any cause, assessed up to 3 years
Secondary outcomes (1)
Incidence of high-grade (>= grade 3) adverse events
Unexpected treatment-related adverse events determined by the treating physician.
Measured: Up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2022
- Study start14 Mar 2023
- Primary completion26 Nov 2025
- Study completion15 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Recurrent Lung Non-Small Cell CarcinomaStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 838 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Responsible party
- Sponsor
- Investigators
- Karen L Reckamp, Principal investigator, SWOG Cancer Research Network
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05633602
- Sponsor's protocol ID
- S2302
- Other IDs
- NCI-2022-09319, S2302, S2302, U10CA180888
- Status last verified
- Apr 2026
- First submitted
- 21 Nov 2022
- Last updated
- 17 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
- ClinicalTrials.gov ID
- NCT05633602
- Acronym / sponsor ID
- S2302
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 838 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
- Study start
- 14 Mar 2023 (actual)
- Primary completion
- 26 Nov 2025 (actual)
- Study completion
- 15 Mar 2028 (estimated)
- First posted
- 1 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Detailed description
PRIMARY OBJECTIVE:
- To compare overall survival (OS) in participants previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC) randomized to pembrolizumab and ramucirumab versus standard of care.
SECONDARY OBJECTIVE:
- To summarize reports of serious and unexpected high-grade (>= grade 3) treatment-related adverse events determined by the treating physician within each treatment arm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive chemotherapy per standard of care on study.
ARM B: Patients receive ramucirumab intravenously (IV) and pembrolizumab IV on study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ARM A (standard of care chemotherapy) | Active comparator | Drug: ChemotherapyPatients receive chemotherapy per standard of care on study. |
| ARM B (ramucirumab, pembrolizumab) | Experimental | Biological: Pembrolizumab, Biological: RamucirumabPatients receive ramucirumab IV and pembrolizumab IV on study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Participants must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) which is stage IV or recurrent
- Participants must have received at least one line of anti-PD-1 or anti-PD-L1 therapy for any stage of NSCLC. Anti-PD-1 or anti-PD-L1 may have been given alone or in combination with other therapy
- Participants must have experienced disease progression (in the opinion of the treating physician) more than (>) 84 days following initiation (cycle 1 day 1) of their most recent anti-PD-1 or PD-L1 therapy
- Participants who received anti-PD-1 or anti-PD-L1 therapy for stage IV or recurrent disease, must have had a best response on anti-PD-1 or anti-PD-L1 therapy of stable, partial response or complete response (in the opinion of the treating physician)
- Participants who received neoadjuvant, adjuvant, and/or consolidation anti-PD-1 or anti-PD-L1 therapy as their only line of anti-PD-1 or anti-PD-L1 therapy must have experienced disease progression within (=<) 365 days from initiation (cycle 1 day 1) of anti-PD-1 or PD-L1 therapy
Key exclusion criteria (2 listed)
- Participants must not have received more than one line of anti-PD-1 or anti-PD-L1 for stage IV or recurrent disease
- Participants must not be receiving or planning to receive another investigational therapy during study participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ChemotherapyAlso: Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, GeneralReceive standard of care chemotherapy | Drug | ARM A (standard of care chemotherapy) |
| PembrolizumabAlso: Keytruda, Lambrolizumab, MK-3475, SCH 900475Given IV | Biological | ARM B (ramucirumab, pembrolizumab) |
| RamucirumabAlso: Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806Given IV | Biological | ARM B (ramucirumab, pembrolizumab) |
Primary outcome
Overall survival
Time frame: From date of randomization to date of death due to any cause, assessed up to 3 years
Assessed in participants with stage IV or recurrent non-small cell lung cancer with acquired resistance to anti-PD-1 or anti-PD-L1 therapy randomized to ramucirumab and pembrolizumab or standard of care chemotherapy. Will use an intention-to-treat analysis and the comparison will be done using a stratified log-rank test. The distribution of overall survival will be estimated using the method of Kaplan-Meier and a Cox proportional hazards model will be used to estimate hazard ratios and associated 95% confidence intervals to estimate treatment effects.
1 secondary outcome
Incidence of high-grade (>= grade 3) adverse events
Time frame: Up to 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2026.
Related trials for Recurrent Lung Non-Small Cell Carcinoma
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingObservational study
Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA
Non-Small Cell Lung Cancer, Minimal Residual Disease
RecruitingPhase 3
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Lung Non-Small Cell Carcinoma
RecruitingPhase 3
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
RecruitingPhase 1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Metastatic Solid Tumor, Recurrent Solid Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Karen L Reckamp principal investigator
SWOG Cancer Research Network
566 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Chemotherapy, Pembrolizumab and Ramucirumab in people with Recurrent Lung Non-Small Cell Carcinoma and Stage IV Lung Cancer AJCC v8, run by SWOG Cancer Research Network at 566 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 17 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 566 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: From date of randomization to date of death due to any cause, assessed up to 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2026.